Last reviewed · How we verify

NAFT500 (adult)

Merz North America, Inc. · FDA-approved active Small molecule

NAFT500 (adult) is a Botulinum toxin type A Small molecule drug developed by Merz North America, Inc.. It is currently FDA-approved for Temporary improvement of moderate to severe glabellar lines (frown lines) in adults. Also known as: NAFT500, naftifine, naftifine hydrochloride.

NAFT500 is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions.

NAFT500 is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions. Used for Temporary improvement of moderate to severe glabellar lines (frown lines) in adults.

At a glance

Generic nameNAFT500 (adult)
Also known asNAFT500, naftifine, naftifine hydrochloride
SponsorMerz North America, Inc.
Drug classBotulinum toxin type A
TargetSNARE complex (acetylcholine release machinery)
ModalitySmall molecule
Therapeutic areaAesthetics / Dermatology
PhaseFDA-approved

Mechanism of action

Botulinum toxin type A irreversibly cleaves SNARE proteins required for acetylcholine vesicle release, leading to temporary paralysis of injected muscles. This mechanism is used therapeutically to reduce dynamic wrinkles and treat various conditions involving muscle hyperactivity. The effect is temporary, typically lasting 3-4 months, after which neuromuscular function gradually recovers.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about NAFT500 (adult)

What is NAFT500 (adult)?

NAFT500 (adult) is a Botulinum toxin type A drug developed by Merz North America, Inc., indicated for Temporary improvement of moderate to severe glabellar lines (frown lines) in adults.

How does NAFT500 (adult) work?

NAFT500 is a botulinum toxin type A preparation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions.

What is NAFT500 (adult) used for?

NAFT500 (adult) is indicated for Temporary improvement of moderate to severe glabellar lines (frown lines) in adults.

Who makes NAFT500 (adult)?

NAFT500 (adult) is developed and marketed by Merz North America, Inc. (see full Merz North America, Inc. pipeline at /company/merz-north-america-inc).

Is NAFT500 (adult) also known as anything else?

NAFT500 (adult) is also known as NAFT500, naftifine, naftifine hydrochloride.

What drug class is NAFT500 (adult) in?

NAFT500 (adult) belongs to the Botulinum toxin type A class. See all Botulinum toxin type A drugs at /class/botulinum-toxin-type-a.

What development phase is NAFT500 (adult) in?

NAFT500 (adult) is FDA-approved (marketed).

What are the side effects of NAFT500 (adult)?

Common side effects of NAFT500 (adult) include Headache, Injection site pain, Eyelid ptosis, Brow ptosis, Facial pain.

What does NAFT500 (adult) target?

NAFT500 (adult) targets SNARE complex (acetylcholine release machinery) and is a Botulinum toxin type A.

Related